Atgam 250mg Injection contains the active ingredient Antithymocyte Immunoglobulins. It is a purified and sterile form of gamma globulin. It is isolated from the hyperimmune plasma of horses immunized with human white blood cell components. It is used after kidney transplantation and other therapies to treat and delay organ rejection. After solid organ transplantation, the body generates an aggressive immune response because it recognizes the transplanted organ's antigens as a foreign antigen. Thus, treatment with immunosuppressive agents is necessary after an organ transplant to prevent organ rejection. Aplastic anemia is a condition characterized by the failure of the bone marrow to produce sufficient blood cells. Atgam 250mg Injections are used to treat severe aplastic anemia, suppress the immune system, and reduce the immune-mediated destruction of bone marrow cells. This helps to restore normal blood cell production. Atgam 250mg Injection can decrease the need for high doses and prolonged use of corticosteroids in immunosuppressive treatments, minimizing side effects and risks. Individuals with known hypersensitivity or previous severe allergic reactions to Atgam 250mg Injection or any of their components should not receive it. Live vaccines should generally be avoided during treatment. Individuals with active infections, particularly severe or systemic infections, should only receive until the infection is adequately treated and resolved.